Advertisement
CGEN vs NBTX
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CGEN is a StrongBuy and NBTX is a StrongBuy.
CGEN's RSI Indicator ascending out of oversold territory
The RSI Indicator for CGEN moved out of oversold territory on October 20, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 43 similar instances when the indicator left oversold territory. In 39 of the 43 cases the stock moved higher. This puts the odds of a move higher at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 49 of 66 cases where CGEN's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 74%.
Following a +9.18% 3-day Advance, the price is estimated to grow further. Considering data from situations where CGEN advanced for three days, in 190 of 233 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
CGEN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Moving Average Convergence Divergence Histogram (MACD) for CGEN turned negative on October 22, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 50 similar instances when the indicator turned negative. In 38 of the 50 cases the stock turned lower in the days that followed. This puts the odds of success at 76%.
CGEN moved below its 50-day moving average on September 23, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for CGEN crossed bearishly below the 50-day moving average on September 23, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 14 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CGEN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
The Aroon Indicator for CGEN entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 20 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 53 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 63 (best 1 - 100 worst), indicating steady price growth. CGEN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 78 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.092) is normal, around the industry mean (2.973). P/E Ratio (5.158) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (3.083) is also within normal values, averaging (438.009).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CGEN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
NBTX's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for NBTX turned positive on October 20, 2026. Looking at past instances where NBTX's MACD turned positive, the stock continued to rise in 38 of 45 cases over the following month. The odds of a continued upward trend are 84%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where NBTX's RSI Indicator exited the oversold zone, 15 of 19 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 79%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 53 of 68 cases where NBTX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 78%.
The Momentum Indicator moved above the 0 level on October 21, 2026. You may want to consider a long position or call options on NBTX as a result. In 81 of 101 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 80%.
Following a +22.53% 3-day Advance, the price is estimated to grow further. Considering data from situations where NBTX advanced for three days, in 188 of 230 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
NBTX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NBTX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.
The Aroon Indicator for NBTX entered a downward trend on October 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 3 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-39.400) is normal, around the industry mean (2.988). P/E Ratio (-23.697) is within average values for comparable stocks, (-1.158). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (123.903) among similar stocks. P/S Ratio (48.077) is also within normal values, averaging (438.009).
The Tickeron PE Growth Rating for this company is 17 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 72 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NBTX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 82 (best 1 - 100 worst), indicating slightly worse than average price growth. NBTX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
CGEN | NBTX | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 87 | 58 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 78 Overvalued | 3 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 72 | |
SMR RATING 1..100 | 20 | 99 | |
PRICE GROWTH RATING 1..100 | 63 | 82 | |
P/E GROWTH RATING 1..100 | 53 | 17 | |
SEASONALITY SCORE 1..100 | 45 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
NBTX's Valuation (3) in the null industry is significantly better than the same rating for CGEN (78) in the Biotechnology industry. This means that NBTX’s stock grew significantly faster than CGEN’s over the last 12 months.
NBTX's Profit vs Risk Rating (72) in the null industry is in the same range as CGEN (100) in the Biotechnology industry. This means that NBTX’s stock grew similarly to CGEN’s over the last 12 months.
CGEN's SMR Rating (20) in the Biotechnology industry is significantly better than the same rating for NBTX (99) in the null industry. This means that CGEN’s stock grew significantly faster than NBTX’s over the last 12 months.
CGEN's Price Growth Rating (63) in the Biotechnology industry is in the same range as NBTX (82) in the null industry. This means that CGEN’s stock grew similarly to NBTX’s over the last 12 months.
NBTX's P/E Growth Rating (17) in the null industry is somewhat better than the same rating for CGEN (53) in the Biotechnology industry. This means that NBTX’s stock grew somewhat faster than CGEN’s over the last 12 months.
| CGEN | NBTX | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 90% | 2 days ago 79% |
| Stochastic ODDS (%) | 1 day ago 74% | 2 days ago 78% |
| Momentum ODDS (%) | N/A | 2 days ago 80% |
| MACD ODDS (%) | 1 day ago 76% | 2 days ago 84% |
| TrendWeek ODDS (%) | 1 day ago 88% | 2 days ago 81% |
| TrendMonth ODDS (%) | 1 day ago 85% | 2 days ago 80% |
| Advances ODDS (%) | 3 days ago 82% | 2 days ago 82% |
| Declines ODDS (%) | 1 day ago 88% | 4 days ago 82% |
| BollingerBands ODDS (%) | 1 day ago 76% | 2 days ago 77% |
| Aroon ODDS (%) | 1 day ago 88% | 2 days ago 85% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
CGEN’s FA Score shows that 1 FA rating(s) are green while NBTX’s FA Score has 2 green FA rating(s).
- CGEN’s FA Score: 1 green, 4 red.
- NBTX’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
CGEN’s TA Score shows that 5 TA indicator(s) are bullish while NBTX’s TA Score has 6 bullish TA indicator(s).
- CGEN’s TA Score: 5 bullish, 4 bearish.
- NBTX’s TA Score: 6 bullish, 2 bearish.
Price Growth
CGEN (@Biotechnology) experienced а -5.77% price change this week, while NBTX (@Biotechnology) price change was +21.38% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -1.17%. For the same industry, the average monthly price growth was -18.21%, and the average quarterly price growth was -15.24%.
Reported Earning Dates
CGEN is expected to report earnings on Nov 09, 2026.
NBTX is expected to report earnings on Nov 17, 2026.
Industries' Descriptions
@Biotechnology (-1.17% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
CGEN and
Correlation & Price change
A.I.dvisor indicates that over the last year, CGEN has been loosely correlated with ORMP. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if CGEN jumps, then ORMP could also see price increases.
| Ticker / NAME | Correlation To CGEN | 1D Price Change % | ||
|---|---|---|---|---|
| CGEN | 100% | -7.55% | ||
| ORMP - CGEN | 40% Loosely correlated | -0.48% | ||
| RCUS - CGEN | 37% Loosely correlated | +1.36% | ||
| RXRX - CGEN | 37% Loosely correlated | -1.65% | ||
| GHRS - CGEN | 36% Loosely correlated | -2.17% | ||
| AXON - CGEN | 36% Loosely correlated | +2.98% | ||
More | ||||
NBTX and
Correlation & Price change
A.I.dvisor tells us that NBTX and CGEN have been poorly correlated (+32% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that NBTX and CGEN's prices will move in lockstep.
| Ticker / NAME | Correlation To NBTX | 1D Price Change % | ||
|---|---|---|---|---|
| NBTX | 100% | +7.00% | ||
| CGEN - NBTX | 32% Poorly correlated | -0.93% | ||
| ASMB - NBTX | 31% Poorly correlated | -3.45% | ||
| CLLS - NBTX | 31% Poorly correlated | -2.17% | ||
| NTLA - NBTX | 30% Poorly correlated | -1.60% | ||
| XBIO - NBTX | 30% Poorly correlated | -1.00% | ||
More | ||||